Author Correction: Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer
Anja Charlotte Lundgren Mortensen, Hanna Berglund, Mehran Hariri, Eleftherios Papalanis, Christer Malmberg, Diana Spiegelberg
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsGlutathione Transferases and Polymorphisms · Thyroid Cancer Diagnosis and Treatment
Correction to: Scientific Reports 10.1038/s41598-023-43486-z, published online 06 October 2023
The original version of this Article contained an error in Figure 3, where due to a mix-up in labelling the results, the 0 h untreated images for MDA-T32 were duplicated and rearranged from the BHT-101 images shown in Figure 3A, which led to incorrect results shown in Figure 3D. The original Figure 3 and accompanying legend appear below.Fig. 3. Wound healing assays of (A) BHT-101 (ATC), (B) SW1736 (ATC), (C) 8305C (ATC) and (D) MDA-T32 (PTC) cells. Cells were treated with 50 nM and 100 nM of onalespib and 15 μM sorafenib. Left column: Bar chart of migrated distance over time. Middle: heat map over migrated distance; Right: Representative images of wound/gap of control, 15 μM sorafenib, 100 nM onalespib and the combination at 0, 6, and 12 h. Values ± SD of 3 independent experiments.
The original Article has been corrected.